Daily Med

Current Medication Information

Options

Download the FDA official PDF of this label

RxNorm Names

nystatin (Nystatinsuspension 
[Bausch & Lomb Incorporated]

Drug Label Sections

DESCRIPTION

Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei. Its structural formula is:

Image from Drug Label Content

C47H75NO17 Mol. Wt. 926.13

Each mL contains 100,000 units of Nystatin in a vehicle containing 50% w/v sucrose with the following inactive ingredients: sodium citrate, glycerin, cherry flavor, carboxymethylcellulose sodium, peppermint flavor, citric acid, alcohol (less than 1% v/v), purified water. Citric acid and/or sodium hydroxide may be added to adjust pH (5.3 - 7.5).

PRESERVATIVES ADDED: Methylparaben 0.12%, Propylparaben 0.03%.

CLINICAL PHARMACOLOGY

Pharmacokinetics

Gastrointestinal absorption of nystatin is insignificant . Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candidaalbicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo.

Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

General

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if

sensitization or irritation is reported during use.

Carcinogenesis, mutagenesis, impairment of fertility

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

Teratogenic effects

Category C. Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Pediatric use

See DOSAGE AND ADMINISTRATION.

ADVERSE REACTIONS

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported.

(See PRECAUTIONS: General.)

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other: Tachycardia, bronchospasm, facial swelling, and nonspecific myalgia have also been rarely reported.

DOSAGE AND ADMINISTRATION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.

HOW SUPPLIED

Nystatin Oral Suspension USP, 100,000 USP Nystatin Units per mL, is available as a yellow, milky, ready-to-use suspension with a cherry-mint flavor in the following sizes:

60 mL bottles (with child-resistant calibrated dropper) - Prod. No. 10721

473 mL bottles - Prod. No. 10729

A 2 mL calibrated dropper with 1 mL calibrations is provided with the 60 mL container.

SHAKE WELL BEFORE USING.

STORAGE

Store between 15°-30°C (59°-86°F).

PROTECT FROM FREEZING

Dispense in a tight, light resistant container when dispensing from the original container.

60 mL: DO NOT USE IF IMPRINTED NECKBAND ON CHILD RESISTANT CAP IS NOT INTACT.

473 mL: DO NOT USE IF IMPRINTED NECKBAND ON CAP IS NOT INTACT.

KEEP OUT OF REACH OF CHILDREN.

MANUFACTURER INFORMATION

Bausch & Lomb Incorporated
Tampa, FL 33637
©Bausch & Lomb Incorporated

Rev July 2005

9011902 (flat)
9012102 (folded)
AB107


Nystatin (Nystatin)
PRODUCT INFO
Product Code24208-960Dosage FormSUSPENSION
Route Of AdministrationORALDEA Schedule
INGREDIENTS
Name (Active Moiety)TypeStrength
Nystatin (Nystatin) Active100000 UNITS  In 1 MILLILITER
AlcoholInactive 
Carboxymethylcellulose SodiumInactive 
Cherry FlavorInactive 
Citric AcidInactive 
GlycerinInactive 
Peppermint FlavorInactive 
WaterInactive 
Sodium CitrateInactive 
Sodium HydroxideInactive 
SucroseInactive 
IMPRINT INFORMATION
CharacteristicAppearanceCharacteristicAppearance
ColorScore
ShapeSymbol
Imprint CodeCoating
Size
PACKAGING
#NDCPackage DescriptionMultilevel Packaging
124208-960-671 BOTTLE In 1 CARTONcontains a BOTTLE, DROPPER
160 MILLILITER In 1 BOTTLE, DROPPERThis package is contained within the CARTON (24208-960-67)
224208-960-94473 MILLILITER In 1 BOTTLENone

Revised: 02/2007

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services